Trial Profile
An Open-Label Study Investigating Long-Term Safety and Tolerability of Nasalfent (Fentanyl Citrate Nasal Spray) in the Treatment of Breakthrough Cancer Pain (BTCP) in Subjects Taking Regular Opioid Therapy.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Jul 2019
Price :
$35
*
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors Archimedes Development Limited
- 03 Jul 2012 Planned number of patients 500 added as reported by EudraCT.
- 03 Jul 2012 Additional trial locations identified as reported by EudraCT.
- 27 Sep 2011 18-month results presented at the 2011 European Multidisciplinary Cancer Congress.